Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/194643
Genomics and epigenomics of substance use disorders: An introduction
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Substance use disorders (SUD) are common conditions around theworld, with important health and societal impacts, particularly inthe burden of disease (disability-adjusted life years) (Whiteford, Fer-rari, Degenhardt, Feigin, & Vos, 2015). The Global Burden of DiseaseStudy estimated the global number of cases for SUD for several sub-stances as follows: 94.8 million for alcohol, 17.2 million for amphet-amine, 15.5 million for opioids, and 13.1 million for cannabis(Whiteford, 2015). In the United States, the lifetime and 12-monthprevalences of SUD were 9.9% and 3.9%, respectively (Grantet al., 2016). In addition, polysubstance use is an important challengein the field of addiction research (Whiteford et al., 2015).
Subject
Subject (English)
Citation
Citation
CORMAND RIFÀ, Bru, et al. Genomics and epigenomics of substance use disorders: An introduction. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2021. Vol. 186, num. 3, pags. 125-127. ISSN 1552-4841. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/194643